TB-500: research overview

Thymosin beta-4 has been reported to upregulate matrix metalloproteinases MMP-1, MMP-2, and MMP-9 in keratinocytes, endothelial cells, fibroblasts, and activated monocytes during wound repair, with the activity localized to the LKKTET central actin-binding domain. MMPs are a family of zinc-dependent endopeptidases — the catalytic site requires a zinc ion — so the matrix-remodelling arm of TB-4 biology is intrinsically gated by zinc availability. Systemic zinc adequacy is therefore a documented permissive cofactor for the proteolytic component of TB-4-driven tissue repair, even though TB-4 itself does not bind zinc. Animal and cell-culture evidence.

Thymosin beta-4 has been reported to upregulate VEGF expression and to drive endothelial-cell migration, tubular formation, and survival via PI3K/Akt and Notch signalling. In a rat MI model, TB-4 pretreatment of endothelial progenitor cells before transplantation improved ejection fraction, reduced scar, and raised microvessel density, with phospho-Akt elevated. This is a mechanistic-cofactor entry rather than a supplement-stacking one: VEGF is the downstream effector that mediates much of TB-4's regenerative output, which is why TB-4 research is often paired with angiogenesis read-outs and progenitor-cell protocols. Animal-model evidence.

Ascorbate is the obligate cofactor for prolyl and lysyl hydroxylases that hydroxylate collagen precursors so the triple helix can fold and be cross-linked. Thymosin beta-4 has been studied across dermal, corneal, and burn wound-healing models in which collagen deposition and granulation tissue maturation are primary endpoints — the same biosynthetic chain that requires ascorbate. Vitamin C is therefore a permissive cofactor for the collagen-deposition arm of TB-4 driven repair, even though the two have not been formally co-administered in published TB-4 protocols. Co-administration is a plausible research stacking choice in dermal-repair contexts.